CDI
Could GI Parasites and Bacterial Infections Be Connected?
Harboring gastrointestinal parasites may increase a person’s risk of developing a C. diff infection, per new ...
AUGUST 6, 2025
Competitor to Vancomycin for C. difficile May Be Coming Soon
The narrow-spectrum antibiotic CRS3123 better preserved gut microbiome diversity than vancomycin in people with ...
JUNE 25, 2025
STOP-CDI Protocol Significantly Reduces Healthcare-Associated C. diff
The Screening and Targeted Prophylaxis for Clostridioides difficile infection (STOP-CDI) protocol, developed at the ...
DECEMBER 14, 2024
Hospital Beds May Increase Risk for C. diff Infection
People who stay in hospital beds, which were previously slept in by a patient with Clostridioides ...
MAY 24, 2024
New Weapon to Prevent C. diff?
Omadacycline had demonstrated a low likelihood of causing C. difficile in clinical trials, but no one ...
JANUARY 2, 2024
FDA Approves First Orally Administered Fecal Microbiota Product to Prevent C. diff Recurrence
The FDA approved the first fecal microbiota product that is taken orally to prevent recurrent CDI in people who are ...
APRIL 27, 2023
2 Steps Are Better Than 1 for CDI Testing
A two-step algorithm for Clostridioides difficile infection (CDI) testing may reduce unnecessary treatment and ...
APRIL 18, 2023
A New Era for Managing Clostridioides difficile Infection
In the last decade, we have started to understand the critical components of the gut microbiome that prevent C. ...
APRIL 3, 2023
Rebyota Now Available for CDI
Rebyota was approved by the FDA on Nov. 30, 2022, to prevent recurrence of Clostridioides ...
FEBRUARY 15, 2023
Phase 3 Data Show Rebyota Safe, Effective in Reducing Recurrent CDI
The FDA approved the microbiota-based live biotherapeutic RBX2660 (Rebyota, Ferring) to prevent recurrent ...
DECEMBER 10, 2022
Worse CDI Outcomes for Minority Patients
Racially and ethnically minoritized persons are more likely to develop severe CDI and have worse clinical outcomes, ...
DECEMBER 5, 2022
FDA Approves Rebyota, the First Live Biotherapeutic Fecal Microbiota Product in the U.S.
RBX2660 (Rebyota, Ferring) is approved by the FDA for the prevention of recurrent Clostridioides difficile ...
DECEMBER 2, 2022
